Search Results - "Greten, T.F."

Second-line treatment in advanced pancreatic cancer: a comprehensive analysis of published clinical trials by Rahma, O.E., Duffy, A., Liewehr, D.J., Steinberg, S.M., Greten, T.F.

“…There is currently no standard of care for the second-line treatment of advanced pancreatic cancer. The aim of this analysis was to compare the different…”
Get full text

Immunological off-target effects of standard treatments in gastrointestinal cancers by Duffy, A.G., Greten, T.F.

“…The effects on immune cells and the inflammatory microenvironment of commonly applied cancer treatments (chemotherapeutic or biologic agents, interventional…”
Get full text

590 QUALITATIVE ANALYSIS OF INTERNATIONAL GUIDELINES FOR DIAGNOSIS AND TREATMENT OF HEPATOCELLULAR CARCINOMA BY THE AGREE INSTRUMENT (APPRAISAL OF GUIDELINES FOR RESEARCH AND EVALUATION) by Schmidt, S, Manns, M.P, Greten, T.F

Get full text

1020 EPIDEMIOLOGICAL TRENDS IN INCIDENCE AND MORTALITY OF HEPATOBILIARY CANCERS IN GERMANY by Von Hahn, T, Ciesek, S, Wegener, G, Weissmueller, T, Manns, M.R, Greten, T.F, Malek, N

Get full text

566 FLUORESCENCE IN SITU HYBRIDIZATION (FISH) ANALYSIS FOR THE DIAGNOSIS OF HCC by Lorber, J, Kreipe, H, Schlegelberger, B, Manns, M.P, Skawran, B, Greten, T.F

Get full text

215 A PHASE II OPEN LABEL TRIAL EVALUATING SAFETY AND EFFICACY OF A TELOMERASE PEPTIDE VACCINATION IN PATIENTS WITH ADVANCED HEPATOCELLULAR CARCINOMA by Greten, T.F, Forner, A, Korangy, F, N'Kontchou, G, Barget, N, Ayuso, C, Ormandy, L, Manns, M, Beaugrand, M, Bruix, J

Get full text

[370] IMPAIRED DENDRITIC CELLS IN TUMORS OF PATIENTS WITH HEPATOCELLULAR CARCINOMA by Ormandy, L.A, Hoechst, B, Lehner, F, Manns, M.P, Korangy, F, Greten, T.F

Get full text

The case for immune‐based approaches in biliary tract carcinoma by Duffy, Austin G., Makarova‐Rusher, Oxana V., Greten, Tim F.

“…Biliary tract cancers (BTC) comprise a group of uncommon malignancies in which the standard therapies are minimally effective and evolve slowly. Like the…”
Get full text

Modulation of tumor eIF4E by antisense inhibition: A phase I/II translational clinical trial of ISIS 183750—an antisense oligonucleotide against eIF4E—in combination with irinotecan in solid tumors and irinotecan‐refractory colorectal cancer by Duffy, A.G., Makarova‐Rusher, O.V., Ulahannan, S.V., Rahma, O.E., Fioravanti, S., Walker, M., Abdullah, S., Raffeld, M., Anderson, V., Abi‐Jaoudeh, N., Levy, E., Wood, B.J., Lee, S., Tomita, Y., Trepel, J.B., Steinberg, S.M., Revenko, A.S., MacLeod, A.R., Peer, C.J., Figg, W.D., Greten, T.F.

“…The eukaryotic translation initiation factor 4E (eIF4E) is a potent oncogene that is found to be dysregulated in 30% of human cancer, including colorectal…”
Get full text

Treating Hepatobiliary Cancer: The Immunologic Approach by Duffy, A G, Greten, T F

“…Hepatobiliary cancer comprises a heterogeneous group of malignancies in which the standard treatments for advanced disease are minimally effective and evolve…”
Get more information

CTLA-4 blockade induces indoleamine 2,3-dioxygenase where treatment with 1- methyl-d-tryptophan displays greater treatment effect in tumors with high ido expression by Brown, Z.J., Heinrich, B., Ma, C., Yu, S.J., Zhang, Q., Fu, Q., Sandhu, M., Agdashian, D., Korangy, F., Greten, T.F.

Get full text

Participation in screening colonoscopy in first-degree relatives from patients with colorectal cancer by Ruthotto, F, Papendorf, F, Wegener, G, Unger, G, Dlugosch, B, Korangy, F, Manns, MP, Greten, TF

“…Background: Current guidelines recommend screening colonoscopy in first-degree relatives of patients with colon cancer. The aim of this state-wide study was to…”
Get full text

Chemoocclusion vs chemoperfusion for treatment of advanced hepatocellular carcinoma: A randomised trial by Kirchhoff, T.D., Rudolph, K.L., Layer, G., Chavan, A., Greten, T.F., Rosenthal, H., Kubicka, S., Galanski, M., Manns, M.P., Schild, H., Gallkowski, U.

“…Transarterial chemoembolization (TACE) can be associated with considerable toxicity and treatment-associated mortality. Transient transarterial chemoocclusion…”
Get full text

Nitric oxide downregulates tumour necrosis factor mRNA in RAW 264.7 cells by Sinha, B., Eigler, A., Baumann, K.H., Greten, T.F., Moeller, J., Endres, S.

“…Nitric oxide (NO) and tumour necrosis factor (TNF) are essential mediators in a number of biological processes, including the immune response. TNF stimulates…”
Get full text